Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 5, Number 3—June 1999


The Cost Effectiveness of Vaccinating against Lyme Disease

Martin I. MeltzerComments to Author , David T. Dennis, and Kathleen A. Orloski
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 2

Costs of treating one case of Lyme disease and the sequelae due to early and late disseminated disease

Item Cost/year
($) Length of treatment Total costsa
Case resolved: no sequelae
Antibiotics 14
Office visits (2) 50
Laboratory tests 35
5 hrs lost work time 62
Total 161 2-3 wks 161
Sequelaeb due to early and 
 late disseminated disease
Cardiac-directc 5,445
Cardiac-indirectd 1,400
Cardiac-total 6,845 < 1 yr 6,845
Neurologic-directc 4,865
Neurologic-indirectd 2,100
Neurologic-total 6,965 11 yrs 61,243
Arthritic-directc 1,804
Arthritic-indirectd 2,100
Arthritic-total 3,904 11 yrs 34,354

aAll costs that occur over more than 1 year are discounted at a rate of 3% per year.
bSee text for description of the sequelae.
cDirect costs are for all medical costs and are derived from the 1-year charges reported by Magid et al. (29), inflated to 1996 dollars (factor of 1.528) (40), and then adjusted by a cost-to-charge ratio of 0.53 (43) (see text for details).
dIndirect costs are the valuation of lost productivity due to Lyme disease-related illness, with each day lost valued at $100. For cardiac-related sequelae, it was assumed that 14 workdays were lost, and for neurologic and arthritic-related sequelae, it was assumed that 21 workdays were lost each year.

Main Article